Is SentinelOne Stock Undervalued?
Cybersecurity major SentinelOne (NYSE:S) has struggled over several years, delivering…
Sell
24
SKYE Quote, Financials, Valuation and Earnings
Last price:
$0.84
Seasonality move
:
-20.14%
Day range:
$0.84 - $0.95
52-week range:
$0.82 - $5.75
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
476.49x
P/B ratio:
0.90x
Volume:
1.1M
Avg. volume:
350.5K
1-year change:
-67.68%
Market cap:
$29.5M
Revenue:
--
EPS (TTM):
-$1.29
Analysts' Opinion
-
Consensus RatingSkye Bioscience, Inc. has received a consensus rating of Buy. The company's average rating is a Buy based on 4 Buy ratings, 2 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $8.25, Skye Bioscience, Inc. has an estimated upside of 796.74% from its current price of $0.85.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $2.00 representing 100% downside risk from its current price of $0.85.
Fair Value
-
According to the consensus of 6 analysts, Skye Bioscience, Inc. has 796.74% upside to fair value with a price target of $8.25 per share.
SKYE vs. S&P 500
-
Over the past 5 trading days, Skye Bioscience, Inc. has underperformed the S&P 500 by -16.76% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Skye Bioscience, Inc. does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Skye Bioscience, Inc. revenues have been falling on a year-over-year basis for 2 quarters in a row. In the most recent quarter Skye Bioscience, Inc. reported revenues of --.
Earnings Growth
-
Skye Bioscience, Inc. earnings have been falling on a year-over-year basis for 3 quarters in a row. In the most recent quarter Skye Bioscience, Inc. reported earnings per share of -$0.32.
Enterprise value:
-5.5M
EV / Invested capital:
-0.17x
Price / LTM sales:
476.49x
EV / EBIT:
--
EV / Revenue:
171.75x
PEG ratio (5yr expected):
-0.01x
EV / Free cash flow:
0.13x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
-$718.6K
Return On Assets:
-81.95%
Net Income Margin (TTM):
--
Return On Equity:
-91.57%
Return On Invested Capital:
-91.01%
Operating Margin:
--
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Income Statement | ||||||
| Revenue | -- | -- | -- | -- | -- | |
| Gross Profit | -$127.4K | -$151.7K | -$718.6K | -$66K | -$178.9K | |
| Operating Income | -$12.7M | -$28.2M | -$55.6M | -$9.5M | -$13.3M | |
| EBITDA | -$12.5M | -$28M | -$54.9M | -$9.5M | -$13.1M | |
| Diluted EPS | -$9.28 | -$0.84 | -$1.29 | -$0.10 | -$0.32 | |
| Period Ending | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2025-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $11.4M | $2.7M | $15.3M | $79.8M | $39.9M | |
| Total Assets | $11.7M | $2.9M | $15.6M | $81.5M | $41.3M | |
| Current Liabilities | $1.5M | $6.1M | $13.7M | $5.6M | $8.4M | |
| Total Liabilities | $3.4M | $6.2M | $13.9M | $5.7M | $8.5M | |
| Total Equity | $8.3M | -$3.3M | $1.7M | $75.8M | $32.8M | |
| Total Debt | $2M | $2.5M | $4.3M | $108.1K | $120.2K | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$15M | -$20.9M | -$41.5M | -$5.3M | -$13.4M | |
| Cash From Investing | $12.3M | -$343K | -$16.6M | -$1.4M | $8M | |
| Cash From Financing | $16.5M | $83.5M | $23.8K | -- | -- | |
| Free Cash Flow | -$14.6M | -$22.5M | -$41.5M | -$6.8M | -$13.4M | |
SKYE
Sector
Market Cap
$29.5M
$28.4M
Price % of 52-Week High
16%
51.17%
Dividend Yield
0%
0%
Shareholder Yield
0.76%
-1.49%
1-Year Price Total Return
-65.93%
-16.67%
Beta (5-Year)
2.676
0.518
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Sell
Level
$1.01
200-day SMA
Sell
Level
$2.47
Bollinger Bands (100)
Sell
Level
1.19 - 3.63
Chaikin Money Flow
Sell
Level
-1.2M
20-day SMA
Sell
Level
$1.13
Relative Strength Index (RSI14)
Sell
Level
28.50
ADX Line
Sell
Level
30.5
Williams %R
Neutral
Level
-79.0509
50-day SMA
Sell
Level
$1.32
MACD (12, 26)
Buy
Level
0.23
25-day Aroon Oscillator
Sell
Level
-96
On Balance Volume
Sell
Level
-3.4M
Financial Scores
Buy
Altman Z-Score
(Annual)
Level (8.3288)
Sell
CA Score
(Annual)
Level (-3.0604)
--
Beneish M-Score
(Annual)
Level (--)
Sell
Momentum Score
Level (1)
Sell
Ohlson Score
Level (9.9174)
--
Piotroski F Score
(Annual)
Level (--)
Sell
Quality Ratio Score
Level (1)
Sell
Fundamental Score
Level (2)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Skye Bioscience, Inc. is a clinical stage biopharmaceutical company, which engages in the development of new medicines that unlock the pharmaceutical potential of the endocannabinoid system to treat diseases caused by metabolic disorders, inflammation, fibrosis, and neurodegeneration. Its products include nimacimab and SBI-100 Ophthalmic Emulsion. The company was founded on March 16, 2011 and is headquartered in San Diego, CA.
Stock Forecast FAQ
In the current month, SKYE has received 4 Buy ratings 2 Hold ratings, and 0 Sell ratings. The SKYE average analyst price target in the past 3 months is $8.25.
-
Where Will Skye Bioscience, Inc. Stock Be In 1 Year?
According to analysts, the consensus estimate is that Skye Bioscience, Inc. share price will rise to $8.25 per share over the next 12 months.
-
What Do Analysts Say About Skye Bioscience, Inc.?
Analysts are divided on their view about Skye Bioscience, Inc. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Skye Bioscience, Inc. is a Sell and believe this share price will drop from its current level to $2.00.
-
What Is Skye Bioscience, Inc.'s Price Target?
The price target for Skye Bioscience, Inc. over the next 1-year time period is forecast to be $8.25 according to 6 Wall Street analysts, 4 of them rate the stock a Buy, 0 rate the stock a Sell, and 2 analysts rate the stock a Hold.
-
Is SKYE A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Skye Bioscience, Inc. is a Buy. 4 of 6 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of SKYE?
You can purchase shares of Skye Bioscience, Inc. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Skye Bioscience, Inc. shares.
-
What Is The Skye Bioscience, Inc. Share Price Today?
Skye Bioscience, Inc. was last trading at $0.84 per share. This represents the most recent stock quote for Skye Bioscience, Inc.. Yesterday, Skye Bioscience, Inc. closed at $0.85 per share.
-
How To Buy Skye Bioscience, Inc. Stock Online?
In order to purchase Skye Bioscience, Inc. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Get SKYE Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
SKYE
Sector
P/E ratio
--
23.89x
PEG ratio
-0.01x
-0.01x
P/B ratio
0.90x
1.81x
Price / LTM sales
476.49x
1.58x
Growth Metrics
SKYE
Sector
Revenue growth
--
4.62%
Earnings growth
-220.32%
10.7%
Revenue (5-year growth)
--
6.5%
Earnings forecast
-$0.32
-$0.21
Profitability
SKYE
Sector
Profitability FY 2024
-$298.6K
$3.6M
Return on invested capital
-91.01%
-31.84%
Return on assets
-81.95%
-27.96%
Return on equity
-91.57%
-37.63%
Earnings Date
Last Earnings Date
Nov
10
Next Earnings Date
Mar
19
Estimated Next Earnings Date
Feb
9
Balance Sheet
SKYE
Sector
Total cash
$35.3M
$26.4M
Short term investments
--
$25.7M
Total assets
$72.8M
$76.9M
Long term debt
$120.2K
$3.3M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Broadcom Stock on Sale?
Chip and software maker Broadcom (NASDAQ:AVGO) has been among the…
Is Bloom Energy The Best Stock to Buy Now?
Shares of energy startup Bloom Energy (NYSE:BE) have advanced by…
Stock Ideas
Buy
55
Is NVDA Stock a Buy?
Market Cap: $4.5T
P/E Ratio: 63x
Buy
53
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 36x
Buy
59
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 39x
Alerts
Buy
60
AAOI alert for Dec 23
Applied Optoelectronics, Inc. [AAOI] is up 3.95% over the past day.
Buy
60
ZBIO alert for Dec 24
Zenas BioPharma, Inc. [ZBIO] is up 1.18% over the past day.
Buy
54
UNF alert for Dec 24
UniFirst Corp. [UNF] is up 0.77% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
